Skip to main content
logo
Monte Rosa Therapeutics logo
Monte Rosa Therapeutics, Inc. (GLUE)
NASDAQ: GLUE · Real-Time Price · USD
10.52
+0.22 (2.14%)
At close: Oct 12, 2026, 4:00 PM EDT
10.54
+0.02 (0.19%)
Pre-market: Oct 13, 2026, 5:28 AM EDT

Monte Rosa Therapeutics Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
28.73123.6775.62---
Revenue Growth
-83.86%63.54%----
Gross Profit
-133.63-10.03-37.24-103.37--
Operating Income
-181.85-54.21-81.11-143.31-112.38-72.88
Net Income
-161.12-38.63-72.7-135.35-108.5-73.96
Earnings Per Share
-1.74-0.46-0.98-2.63-2.30-2.96
EPS Growth
------

Cash & Debt
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
621.1377.1372.15232.41262.83346.07
Total Debt
37.9939.1942.7246.0447-
Net Cash (Debt)
583.12337.91329.43186.37215.83346.07
Net Cash Growth
133.75%2.57%76.76%-13.65%-37.64%729.93%
Net Cash Per Share
6.324.074.463.634.5713.84

Cash Flow & CapEx
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-24.07-22.842-43.8-92.47-59.36
Capital Expenditures
-8.01-4.7-3.99-19.04-12.91-9.73
Free Cash Flow
-32.08-27.538.01-62.84-105.38-69.1
Free Cash Flow Growth
------

Margins
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
--8.11%-49.25%---
Operating Margin
-633.04%-43.83%-107.26%---
Pretax Margin
-570.80%-32.12%-92.74%---
Profit Margin
-560.85%-31.23%-96.14%---
FCF Margin
-111.66%-22.23%50.26%---

Valuation
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingOct '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
P/FCF Ratio
--11.22---
PS Ratio
31.248.265.64---